Medical Diagnostics

Shrink Technologies, Inc.

BRIEF DESCRIPTION

Shrink Technologies, Inc., based in Carlsbad, California, was acquired by Shrink Nanotechnologies, Inc. on May 29, 2009. Shrink Technologies specializes in developing innovative technologies, particularly focused on metal-enhanced fluorescence (MEF) applications. Their MEF technology, which integrates rapid prototyping methods with metal-fluorescence enhanced immunoassays, significantly enhances the sensitivity of diagnostic assays, making it possible to detect interactions that current methods miss. This technology has broad applications in drug discovery,...

OncoRx Pharmaceuticals, Inc.

Brief Description

OncoRx Pharmaceuticals is an early-stage pharmaceutical company discovering and developing targeted therapies that control the progression of invasive malignant cancer. OncoRx has identified and tested drugs that markedly alter the sustained directional mobility, the uncontrolled cell cycle, and t​​he unrestrained growth and proliferation of intrinsically and acquired therapy-resistant tumors. Unlike non-aggressive primary tumors, the growth, progression and invasiveness of therapy-resistant tumors are not effectively controlled with currently available cancer therapies...

O.N. Diagnostics, LLC

Brief Description

O.N. Diagnostics was founded in 2005 by Prof. Tony M. Keaveny (UC Berkeley) based on biomedical engineering research conducted at UC Berkeley and UC San Francisco. Our mission is to improve patient outcomes by developing non-invasive and clinically effective diagnostic applications that quantitatively exploit the richness of information in CT scans. Since inception, our approach has been consistent: achieve scientific and technological excellence through rigorous research and validation, combined with the highest industry standards in execution and quality control...

Nodexus, Inc.

Brief Description Nodexus is commercializing an integrated, “one-click” platform that is low-cost, compact, and provides a simplified workflow to deliver enriched single cells of interest from a wide variety of samples such as stem cells, transfected cell lines, cultured cell lines, dissociated tissue, and whole blood. Timeline 2014. Company founded. Inventors Lydia Sohn

BioScale, Inc.

Brief Description

BioScale developed diagnostic solutions that address critical unmet needs in population health and chronic care. An area of focus has been vulnerable populations such as those with chronic obstructive pulmonary disease, diabetes, and cardiovascular disease. The company's algorithms utilized combinations of blood-based biomarkers for identifying individuals at high risk for severe outcomes. BioScale's rigorous approach to test development included collaborating with leading academic medical centers and validating assays in large, carefully curated cohorts.

Bioscale...

BioAmp Diagnostics

Brief Description

BioAmp develops novel, instrument-free screening and diagnostic tools to identify antibiotic-resistant bacteria in patient samples.

Timeline 2017. Company founded, and participated in the Citris Foundry accelerator program Inventors

Tara DeBoer, Niren Murthy, Jessica Marie Palomino, Lee Woodland Riley

Rewrite Therapeutics

Brief Description

Rewrite Therapeutics accelerates drug development using a proprietary CRISPR-based evolution platform. For more information, contact Shakked Halperin.

Formerly known as Evolve Biotech, and Rewrite Biotech.

The company was acquired by Intellia Therapeutics in 2022.

Timeline 2018. Company founded 2022. Acquired by Intellia Therapeutics Inventor

Shakked Halperin

Synvivia, Inc.

Brief Description Synvivia is an early-stage Synthetic Biology startup located in QB3-EBIC in Berkeley, CA. Synvivia's technology was developed at UC Berkeley with grants from the NSF and DARPA. The work was published in ACS Synthetic Biology and featured as an Editor’s Choice in Science Magazine.

Synvivia has exclusive license to IP in all fields of use. Backed by Y Combinator, the National Institutes of Health, and industrial partnership, Synvivia is building genetically encoded biocontainment technologies that will enable the widespread use of synthetic biology outside of the laboratory...

Tenaya Therapeutics

Brief Description

Tenaya Therapeutics is shaping the future of heart disease treatment driven by a mission to discover, develop, and deliver curative therapies that address the underlying drivers of heart disease. Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three platforms: Gene Therapy, Cellular Regeneration, and Precision Medicine. Founded in 2016 by leading cardiology researchers at the Gladstone Institutes and UT Southwestern, Tenaya is backed by a top-tier syndicate of investors.

Inventors Bruce Conklin, Kevin...

GenEdit, Inc.

BRIEF DESCRIPTION

GenEdit was founded by UC Berkeley scientists who developed targeted delivery technologies for CRISPR therapeutics. The GenEdit founders share the vision that recent scientific advancements in engineering CRISPR components and delivery vehicles offer a groundbreaking opportunity to develop safe and effective medicines for genetic diseases.

Our proprietary Polymer nanoparticle can deliver CRISPR protein and gRNA. Despite CRISPR in a protein form has many advantages, delivery has been a challenge limiting its application. To deliver CRISPR protein, encapsulation of...